Craft
Abivax

Abivax

Patent Families

29

FY, 2018

Market Capitalization

€133.5 M

2022-11-18

Abivax Summary

Company summary

Overview
Abivax is a biotech company that mobilizes the body’s natural immune system to treat patients suffering from inflammatory diseases, infectious diseases, and cancer. It leverages its immune-enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (ABX464), HIV (ABX464), and liver cancer (ABX196).
Type
Public
Status
Active
Founded
2013
HQ
Paris, FR | view all locations
Website
http://www.abivax.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key people

  • Hartmut J. Ehrlich

    Hartmut J. Ehrlich, Chief Executive Officer

  • Didier Blondel

    Didier Blondel, Executive Vice President, Chief Financial Officer and Director

  • Paul Gineste

    Paul Gineste, Vice President of Clinical Operations

  • Pierre Courteille

    Pierre Courteille, Chief Commercial Officer and Vice President Business Development

Operating MetricsView all

Patents Issued

243
12.0%

FY, 2018

Patent Families

29
11.5%

FY, 2018

Patents Pending

120
9.8%

FY, 2018

LocationsView all

2 locations detected

  • Paris, IDF HQ

    France

    5 Rue de la Baume

  • Montpellier, Occitanie

    France

    1919 Route de Mende

Abivax Financials

Summary financials

Gross profit (H1, 2022)
(€15.8M)
Net income (H1, 2022)
(€29.6M)
Cash (H1, 2022)
€26.6M
EBIT (H1, 2022)
(€29.7M)
Enterprise value
$156.4M

News

Footer menu